<?xml version="1.0" encoding="UTF-8"?>
<p id="p0160">These viral entry blockages include chloroquine, hydroxychloroquine umifenovir, and interferon [
 <xref rid="bb0560" ref-type="bibr">112</xref>]. A cell line study reported that chloroquine significantly decreased the human coronavirus-229E replication at a lower concentration than the clinical dosage [
 <xref rid="bb0565" ref-type="bibr">113</xref>]. A systematic review suggested the rationale, pre-clinical supporting evidence of the effectiveness against SARS-CoV-II, and the clinical safety profiles, that justify future clinical research of chloroquine and hydroxychloroquine in patients with COVID-19 [
 <xref rid="bb0570" ref-type="bibr">114</xref>].
</p>
